You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMycophenolate mofetil
Accession NumberDB00688  (APRD01602)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionMycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent, inosine monophosphate dehydrogenase (IMPDH) inhibitor.
Structure
Thumb
Synonyms
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Cellcept
MMF
Mycophenolic acid morpholinoethyl ester
RS 61443
External Identifiers
  • 168396
  • RS 61443
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-mycophenolate Mofetil CapsulesCapsule250 mgOralAccel Pharma IncNot applicableNot applicableCanada
Accel-mycophenolate Mofetil TabletsTablet500 mgOralAccel Pharma IncNot applicableNot applicableCanada
Ach-mycophenolateCapsule250 mgOralAccord Healthcare Inc2012-05-01Not applicableCanada
CellceptCapsule250 mg/1OralCardinal Health1995-05-03Not applicableUs
CellceptCapsule250 mg/1OralGenentech, Inc.1995-05-03Not applicableUs
CellceptCapsule250 mgOralRoche Registration Ltd.1996-02-14Not applicableEu
CellceptPowder, for suspension200 mgOralHoffmann La Roche Limited2002-08-27Not applicableCanada
CellceptCapsule250 mg/1OralRebel Distributors Corp1995-05-03Not applicableUs
CellceptCapsule250 mgOralHoffmann La Roche Limited1995-12-31Not applicableCanada
CellceptTablet, film coated500 mg/1OralGenentech, Inc.1997-06-19Not applicableUs
CellceptInjection, powder, for solution500 mgIntravenousRoche Registration Ltd.1996-02-14Not applicableEu
CellceptCapsule250 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-29Not applicableUs
CellceptTablet500 mgOralHoffmann La Roche Limited1998-11-11Not applicableCanada
CellceptPowder, for suspension200 mg/mLOralGenentech, Inc.1998-10-01Not applicableUs
CellceptTablet500 mgOralRoche Registration Ltd.1996-02-14Not applicableEu
CellceptTablet, film coated500 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1997-06-19Not applicableUs
CellceptInjection, powder, lyophilized, for solution500 mg/20mLIntravenousGenentech, Inc.1998-08-12Not applicableUs
CellceptTablet500 mgOralRoche Registration Ltd.1996-02-14Not applicableEu
CellceptCapsule250 mgOralRoche Registration Ltd.1996-02-14Not applicableEu
Cellcept I.V.Powder, for solution500 mgIntravenousHoffmann La Roche Limited1999-12-20Not applicableCanada
Co MycophenolateTablet500 mgOralCobalt Pharmaceuticals Company2012-02-14Not applicableCanada
Jamp-mycophenolateTablet500 mgOralJamp Pharma Corporation2012-03-23Not applicableCanada
Jamp-mycophenolate CapsulesCapsule250 mgOralJamp Pharma Corporation2012-06-13Not applicableCanada
Mycophenolate MofetilCapsule250 mgOralSanis Health Inc2016-09-29Not applicableCanada
Mycophenolate MofetilTablet500 mgOralSanis Health Inc2016-09-29Not applicableCanada
Mycophenolate Mofetil for Injection, USPPowder, for solution500 mgIntravenousAccord Healthcare IncNot applicableNot applicableCanada
Mycophenolate Mofetil TabletsTablet500 mgOralAccord Healthcare Inc2012-02-16Not applicableCanada
Mylan-mycophenolateTablet500 mgOralMylan Pharmaceuticals Ulc2011-11-30Not applicableCanada
Mylan-mycophenolateCapsule250 mgOralMylan Pharmaceuticals Ulc2011-11-30Not applicableCanada
Novo-mycophenolateTablet500 mgOralTeva Canada Limited2011-11-30Not applicableCanada
Novo-mycophenolateCapsule250 mgOralTeva Canada Limited2011-11-30Not applicableCanada
Ran-mycophenolateTablet500 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Sandoz Mycophenolate MofetilTablet500 mgOralSandoz Canada Incorporated2011-11-30Not applicableCanada
Sandoz Mycophenolate MofetilCapsule250 mgOralSandoz Canada Incorporated2011-11-30Not applicableCanada
Van-mycophenolateCapsule250 mgOralVanc Pharmaceuticals Inc2015-07-22Not applicableCanada
Van-mycophenolateTablet500 mgOralVanc Pharmaceuticals Inc2015-07-22Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-mycophenolateCapsule250 mgOralApotex Inc2011-12-01Not applicableCanada
Apo-mycophenolateTablet500 mgOralApotex Inc2011-12-01Not applicableCanada
Mycophenolate MofetilTablet, film coated500 mg/1OralMylan Institutional Inc.2009-06-01Not applicableUs
Mycophenolate MofetilPowder, for suspension200 mg/mLOralAscend Laboratories, LLC2014-11-17Not applicableUs
Mycophenolate MofetilTablet, film coated500 mg/1OralA S Medication Solutions2010-11-06Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralTeva Pharmaceuticals USA Inc2009-05-06Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralGolden State Medical Supply, Inc.2015-01-06Not applicableUs
Mycophenolate MofetilTablet500 mg/1OralQualitest Pharmaceuticals2010-07-192015-12-29Us
Mycophenolate MofetilCapsule250 mg/1OralJUBILANT CADISTA PHARMACEUTICALS, INC.2013-08-01Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralZydus Pharmaceuticals (USA) Inc.2009-05-04Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralCadila Healthcare Limited2009-05-04Not applicableUs
Mycophenolate MofetilTablet, film coated500 mg/1OralStrides Shasun Limited2010-11-06Not applicableUs
Mycophenolate MofetilTablet500 mg/1OralSandoz Inc2008-10-15Not applicableUs
Mycophenolate MofetilTablet500 mg/1OralAmerican Health Packaging2014-12-15Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralMylan Institutional Inc.2009-06-01Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralAscend Laboratories, LLC2010-01-01Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralWest Ward Pharmaceuticals Corp2008-07-29Not applicableUs
Mycophenolate MofetilTablet, film coated500 mg/1OralTeva Pharmaceuticals USA Inc2009-05-05Not applicableUs
Mycophenolate MofetilTablet, film coated500 mg/1OralGolden State Medical Supply, Inc.2015-01-06Not applicableUs
Mycophenolate MofetilTablet, coated500 mg/1OralAmerican Health Packaging2012-07-022015-12-31Us
Mycophenolate MofetilTablet, film coated500 mg/1OralJUBILANT CADISTA PHARMACEUTICALS, INC.2013-08-01Not applicableUs
Mycophenolate MofetilTablet, film coated500 mg/1OralZydus Pharmaceuticals (USA) Inc.2009-05-04Not applicableUs
Mycophenolate MofetilTablet500 mg/1OralAccord Healthcare Inc.2009-05-04Not applicableUs
Mycophenolate MofetilTablet, film coated500 mg/1OralCadila Healthcare Limited2009-05-04Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralStrides Shasun Limited2010-11-06Not applicableUs
Mycophenolate MofetilInjection, powder, lyophilized, for solution500 mg/20mLIntravenousPar Pharmaceutical, Inc.2016-10-28Not applicableUs
Mycophenolate MofetilTablet500 mg/1OralCardinal Health2011-10-25Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralAmerican Health Packaging2012-07-02Not applicableUs
Mycophenolate MofetilTablet500 mg/1OralWest Ward Pharmaceuticals Corp2008-07-29Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralMylan Pharmaceuticals Inc.2009-05-04Not applicableUs
Mycophenolate MofetilTablet, coated500 mg/1OralApotex Corp2009-05-04Not applicableUs
Mycophenolate MofetilTablet, film coated500 mg/1OralGreenstone LLC2010-06-11Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralAccord Healthcare Inc.2009-05-04Not applicableUs
Mycophenolate MofetilTablet, film coated500 mg/1OralAscend Laboratories, LLC2011-11-28Not applicableUs
Mycophenolate MofetilTablet, film coated500 mg/1OralAv Pak2016-08-25Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralCardinal Health2011-10-25Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralAmerican Health Packaging2014-12-15Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralSandoz Inc2008-10-15Not applicableUs
Mycophenolate MofetilTablet, film coated500 mg/1OralMylan Pharmaceuticals Inc.2009-05-04Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralApotex Corp2009-05-04Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralGreenstone LLC2010-06-11Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralQualitest Pharmaceuticals2010-03-162015-12-29Us
Mycophenolate Mofetil TevaTablet, film coated500 mgOralTeva Pharma B.V.2008-02-21Not applicableEu
Mycophenolate Mofetil TevaCapsule250 mgOralTeva Pharma B.V.2008-02-21Not applicableEu
Mycophenolate Mofetil TevaTablet, film coated500 mgOralTeva Pharma B.V.2008-02-21Not applicableEu
Mycophenolate Mofetil TevaCapsule250 mgOralTeva Pharma B.V.2008-02-21Not applicableEu
Mycophenolate Mofetil TevaCapsule250 mgOralTeva Pharma B.V.2008-02-21Not applicableEu
Mycophenolate Mofetil TevaTablet, film coated500 mgOralTeva Pharma B.V.2008-02-21Not applicableEu
MyfenaxCapsule250 mgOralTeva B.V.2008-02-21Not applicableEu
MyfenaxCapsule250 mgOralTeva B.V.2008-02-21Not applicableEu
MyfenaxTablet, film coated500 mgOralTeva B.V.2008-02-21Not applicableEu
MyfenaxTablet, film coated500 mgOralTeva B.V.2008-02-21Not applicableEu
MyfenaxCapsule250 mgOralTeva B.V.2008-02-21Not applicableEu
MyfenaxTablet, film coated500 mgOralTeva B.V.2008-02-21Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CellCept Oral Suspension Genentech USA, Inc.
CellCept IntravenousGenentech USA, Inc.
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Mycophenolate mofetil hydrochloride
116680-01-4
Thumb
  • InChI Key: OWLCGJBUTJXNOF-HDNKIUSMSA-N
  • Monoisotopic Mass: 469.1867301
  • Average Mass: 469.96
DBSALT001477
Categories
UNII9242ECW6R0
CAS number128794-94-5
WeightAverage: 433.4947
Monoisotopic: 433.210052351
Chemical FormulaC23H31NO7
InChI KeyRTGDFNSFWBGLEC-SYZQJQIISA-N
InChI
InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+
IUPAC Name
2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate
SMILES
COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C
Pharmacology
IndicationFor the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. Mycophenolate mofetil should be used concomitantly with cyclosporine and corticosteroids.
Structured Indications
PharmacodynamicsMycophenolate mofetil is a prodrug of mycophenolic acid (MPA), an antibiotic substance derived from Penicillium stoloniferum. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites.
Mechanism of actionMycophenolate mofetil is hydrolyzed to form mycophenolic acid (MPA), which is the active metabolite. MPA is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines, whereas other cell types can utilize salvage pathways, MPA has potent cytostatic effects on lymphocytes. MPA inhibits proliferative responses of T- and B-lymphocytes to both mitogenic and allospecific stimulation. Addition of guanosine or deoxyguanosine reverses the cytostatic effects of MPA on lymphocytes. MPA also suppresses antibody formation by B-lymphocytes. MPA prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection. Mycophenolate mofetil did not inhibit early events in the activation of human peripheral blood mononuclear cells, such as the production of interleukin-1 (IL-1) and interleukin-2 (IL-2), but did block the coupling of these events to DNA synthesis and proliferation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Inosine-5'-monophosphate dehydrogenase 1Proteinyes
inhibitor
HumanP20839 details
Inosine-5'-monophosphate dehydrogenase 2Proteinyes
inhibitor
HumanP12268 details
Related Articles
AbsorptionRapidly absorbed following oral administration. In 12 healthy volunteers, the mean absolute bioavailability of oral mycophenolate mofetil relative to intravenous mycophenolate mofetil (based on MPA AUC) was 94%. The absolute bioavailability of the delayed release tablet in stable renal transplant patients on cyclosporin is 72%. Food (27 g fat, 650 calories) has no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil.
Volume of distribution
  • 3.6 ±1.5 L/kg [intravenous, healthy subjects, MPA]
  • 4 ±1.2 L/kg [oral administration, healthy subjects, MPA]
Protein bindingMPA (the active metabolite), at clinically relevant concentrations, is over 98% bound to plasma albumin. The phenolic glucuronide of MPA, mycophenolic acid glucuronide (MPAG) has 82% protein bound.
Metabolism

Following oral and intravenous dosing, mycophenolate mofetil undergoes complete metabolism to MPA, the active metabolite. Metabolism to MPA occurs presystemically after oral dosing. MPA is metabolized principally by glucuronyl transferase to form the phenolic glucuronide of MPA (MPAG) which is not pharmacologically active. In vivo, MPAG is converted to MPA via enterohepatic recirculation. The following metabolites of the 2-hydroxyethyl-morpholino moiety are also recovered in the urine following oral administration of mycophenolate mofetil to healthy subjects: N-(2-carboxymethyl)-morpholine, N-(2-hydroxyethyl)-morpholine, and the N-oxide of N-(2-hydroxyethyl)-morpholine. Cytochrome P450 isozymes, CYP3A4/5 and to a lesser extent by CYP2C8, is responsible for the biotransformation of MPA to 6-O-desmethyl-mycophenolic acid.

SubstrateEnzymesProduct
Mycophenolate mofetil
Not Available
Mycophenolic acid (MPA)Details
Mycophenolate mofetil
Not Available
Mycophenolic acid glucuronideDetails
Mycophenolate mofetil
Not Available
N-(2-carboxymethyl)-morpholineDetails
Mycophenolate mofetil
Not Available
N-(2-hydroxyethyl)-morpholineDetails
Mycophenolate mofetil
Not Available
N-(2-hydroxyethyl)-morpholine N-oxideDetails
Route of eliminationNegligible amount of drug is excreted as MPA (< 1% of dose) in the urine. When orally administered, mycophenolate mofetil was completely recovered with 93% of the dose found in the urine and 6% found in feces. 87% of the administered dose is excreted in the urine as MPAG.
Half lifeThe mean elimination half-life for mycophenolic acid (the active metabolite) ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.
Clearance
  • 193 mL/min [plasma clearance, MPA, oral administration]
  • 177 mL/min [plasma clearance, MPA, IV administration]
  • 15.5 mL/min [renal clearance, MPAG, delayed-release tablet]
ToxicityOral (LD50): Acute: 352 mg/kg [Rat], 1000 mg/kg [Mouse], and >6000 mg/kg [Rabbit]. Possible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Mycophenolic Acid Metabolism PathwayDrug metabolismSMP00652
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with 5-androstenedione.Experimental, Illicit
AbciximabMycophenolate mofetil may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Abiraterone.Approved
AcebutololMycophenolate mofetil may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Aceclofenac.Approved
AcenocoumarolMycophenolate mofetil may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Acetaminophen.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinMycophenolate mofetil may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Mycophenolate mofetil.Approved
AfatinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Alclometasone.Approved
AldosteroneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Alectinib.Approved
Alendronic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Alendronic acid.Approved
AlfentanilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Alfentanil.Approved, Illicit
AliskirenMycophenolate mofetil may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololMycophenolate mofetil may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
ALT-110The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with ALT-110.Investigational
AmantadineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Amantadine.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Amcinonide.Approved
AmikacinMycophenolate mofetil may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideMycophenolate mofetil may decrease the antihypertensive activities of Amiloride.Approved
Aminohippuric acidThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Mycophenolate mofetil can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Amprenavir.Approved
AmrubicinMycophenolate mofetil may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AmsacrineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Amsacrine.Approved
AncrodMycophenolate mofetil may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Anisodamine.Investigational
annamycinMycophenolate mofetil may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Antipyrine.Approved
Antithrombin III humanMycophenolate mofetil may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Mycophenolate mofetil may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanMycophenolate mofetil may increase the anticoagulant activities of Apixaban.Approved
ApramycinMycophenolate mofetil may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinMycophenolate mofetil may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinMycophenolate mofetil may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanMycophenolate mofetil may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololMycophenolate mofetil may decrease the antihypertensive activities of Arotinolol.Approved
AstemizoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Mycophenolate mofetil can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Atorvastatin.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Azapropazone.Withdrawn
AzelastineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mycophenolate mofetil.Approved
AzithromycinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Azithromycin.Approved
BalsalazideMycophenolate mofetil may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Mycophenolate mofetil.Investigational
BecaplerminMycophenolate mofetil may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMycophenolate mofetil may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mycophenolate mofetil.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mycophenolate mofetil.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Benoxaprofen.Withdrawn
BenzocaineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Bepridil.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mycophenolate mofetil.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Betamethasone.Approved, Vet Approved
BetaxololMycophenolate mofetil may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Betulinic Acid.Investigational
BevantololMycophenolate mofetil may decrease the antihypertensive activities of Bevantolol.Approved
BexaroteneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
BiperidenThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Biperiden.Approved
BisoprololMycophenolate mofetil may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMycophenolate mofetil may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Mycophenolate mofetil can be decreased when combined with Boceprevir.Approved
BopindololMycophenolate mofetil may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Mycophenolate mofetil can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Bosutinib.Approved
BromfenacThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Bromocriptine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bucillamine.Investigational
BucindololMycophenolate mofetil may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Budesonide.Approved
BufuralolMycophenolate mofetil may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideMycophenolate mofetil may decrease the diuretic activities of Bumetanide.Approved
BupranololMycophenolate mofetil may decrease the antihypertensive activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Candesartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mycophenolate mofetil.Experimental
CaptoprilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Mycophenolate mofetil can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mycophenolate mofetil.Approved
CarprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololMycophenolate mofetil may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Caspofungin.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Castanospermine.Experimental
CDX-110The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Celecoxib.Approved, Investigational
CeliprololMycophenolate mofetil may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ceritinib.Approved
CertoparinMycophenolate mofetil may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Vet Approved
ChlorpromazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mycophenolate mofetil.Approved
CholesterolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cholesterol.Experimental
CholestyramineCholestyramine can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cholic AcidThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Cholic Acid.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ciclesonide.Approved, Investigational
CilazaprilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Cimetidine.Approved
CinoxacinMycophenolate mofetil may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Citalopram.Approved
Citric AcidMycophenolate mofetil may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Mycophenolate mofetil can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Mycophenolate mofetil can be decreased when combined with Clemastine.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clodronate.Approved, Investigational, Vet Approved
ClofazimineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clonixin.Approved
ClopidogrelThe metabolism of Mycophenolate mofetil can be decreased when combined with Clopidogrel.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Mycophenolate mofetil.Vet Approved
ClotrimazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Mycophenolate mofetil can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColforsinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Cortisone acetate.Approved
CrizotinibThe metabolism of Mycophenolate mofetil can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Curcumin.Investigational
CyclophosphamideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineMycophenolate mofetil may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Mycophenolate mofetil can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with D-Limonene.Investigational
Dabigatran etexilateMycophenolate mofetil may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dactinomycin.Approved
DalteparinMycophenolate mofetil may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMycophenolate mofetil may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarunavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinMycophenolate mofetil may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Mycophenolate mofetil can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Mycophenolate mofetil.Approved
DesipramineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Desipramine.Approved
DesirudinMycophenolate mofetil may increase the anticoagulant activities of Desirudin.Approved
DesloratadineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Mycophenolate mofetil.Approved
DextranMycophenolate mofetil may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Mycophenolate mofetil may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Mycophenolate mofetil may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Mycophenolate mofetil may increase the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mycophenolate mofetil.Approved, Vet Approved
DiclofenacThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolMycophenolate mofetil may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mycophenolate mofetil.Approved
DihydroergotamineThe metabolism of Mycophenolate mofetil can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinMycophenolate mofetil may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DiltiazemThe metabolism of Mycophenolate mofetil can be decreased when combined with Diltiazem.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Mycophenolate mofetil.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Mycophenolate mofetil.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Mycophenolate mofetil.Approved
DipyridamoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dipyridamole.Approved
DoxazosinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Doxepin.Approved
DoxorubicinMycophenolate mofetil may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Mycophenolate mofetil can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Mycophenolate mofetil can be decreased when combined with Dronedarone.Approved
DrospirenoneMycophenolate mofetil may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ebselen.Investigational
Edetic AcidMycophenolate mofetil may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMycophenolate mofetil may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Elbasvir.Approved
EltrombopagThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mycophenolate mofetil.Approved
EnoxacinMycophenolate mofetil may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinMycophenolate mofetil may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Epirizole.Approved
EpirubicinMycophenolate mofetil may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneMycophenolate mofetil may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mycophenolate mofetil.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mycophenolate mofetil.Approved
EquileninThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Equilin.Approved
ErgonovineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ergotamine.Approved
ErythromycinThe metabolism of Mycophenolate mofetil can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololMycophenolate mofetil may decrease the antihypertensive activities of Esmolol.Approved
EstramustineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Estrone sulfate.Approved
Etacrynic acidMycophenolate mofetil may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Mycophenolate mofetil.Approved, Investigational
Ethyl biscoumacetateMycophenolate mofetil may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etofenamate.Approved
EtoposideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with exisulind.Investigational
FelodipineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mycophenolate mofetil.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Mycophenolate mofetil.Vet Approved
FentanylThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fidaxomicin.Approved
FingolimodMycophenolate mofetil may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinMycophenolate mofetil may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Mycophenolate mofetil.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with fluasterone.Investigational
FluconazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fludrocortisone.Approved
FluindioneMycophenolate mofetil may increase the anticoagulant activities of Fluindione.Investigational
FlumequineMycophenolate mofetil may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluorometholone.Approved
FluoxetineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Mycophenolate mofetil.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flurandrenolide.Approved
FlurazepamThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Mycophenolate mofetil can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mycophenolate mofetil.Approved, Nutraceutical, Vet Approved
FondaparinuxMycophenolate mofetil may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMycophenolate mofetil may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Mycophenolate mofetil.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mycophenolate mofetil.Approved
FosphenytoinThe metabolism of Mycophenolate mofetil can be increased when combined with Fosphenytoin.Approved
FramycetinMycophenolate mofetil may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideMycophenolate mofetil may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with G17DT.Investigational
GabexateMycophenolate mofetil may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinMycophenolate mofetil may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Gefitinib.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Mycophenolate mofetil.Approved, Withdrawn
GemfibrozilThe metabolism of Mycophenolate mofetil can be decreased when combined with Gemfibrozil.Approved
GemifloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinMycophenolate mofetil may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Genistein.Investigational
GentamicinMycophenolate mofetil may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMycophenolate mofetil may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GI-5005The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with GI-5005.Investigational
GlyburideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with HE3286.Investigational
HeparinMycophenolate mofetil may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Higenamine.Investigational
HirulogMycophenolate mofetil may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with HMPL-004.Investigational
HydralazineMycophenolate mofetil may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Vet Approved
HydrocortisoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mycophenolate mofetil.Approved
Hygromycin BMycophenolate mofetil may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Icatibant.Approved
IdarubicinMycophenolate mofetil may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdelalisibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Idelalisib.Approved
idraparinuxMycophenolate mofetil may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
ImatinibThe metabolism of Mycophenolate mofetil can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Mycophenolate mofetil.Investigational
ImipramineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Imipramine.Approved
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mycophenolate mofetil.Approved
IndenololMycophenolate mofetil may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Indoprofen.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with INGN 225.Investigational
INNO-206Mycophenolate mofetil may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Mycophenolate mofetil can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Mycophenolate mofetil can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Isoxicam.Withdrawn
IsradipineThe metabolism of Mycophenolate mofetil can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ivermectin.Approved, Vet Approved
KanamycinMycophenolate mofetil may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Kebuzone.Experimental
KetamineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mycophenolate mofetil.Approved
LabetalolMycophenolate mofetil may decrease the antihypertensive activities of Labetalol.Approved
LansoprazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lapatinib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Leflunomide.Approved, Investigational
LepirudinMycophenolate mofetil may increase the anticoagulant activities of Lepirudin.Approved
LevobunololMycophenolate mofetil may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lidocaine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Mycophenolate mofetil.Approved
LiothyronineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Mycophenolate mofetil.Approved
LomefloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Lomefloxacin.Approved
LomitapideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Loratadine.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lornoxicam.Approved
LosartanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Mycophenolate mofetil can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
LuliconazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Mycophenolate mofetil.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Magnesium salicylate.Approved
MaprotilineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Maprotiline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mycophenolate mofetil.Approved
ME-609The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with ME-609.Investigational
MebendazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mebendazole.Approved, Vet Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mefenamic acid.Approved
MefloquineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Meloxicam.Approved, Vet Approved
MeprobamateThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMycophenolate mofetil may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Metamizole.Withdrawn
MethadoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mycophenolate mofetil.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolate mofetil.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Methylprednisolone.Approved, Vet Approved
MetipranololMycophenolate mofetil may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolate mofetil.Approved
MetoprololThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Metoprolol.Approved, Investigational
MetrizamideMycophenolate mofetil may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MibefradilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mycophenolate mofetil.Approved
MitomycinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mizoribine.Investigational
ModafinilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mycophenolate mofetil.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mycophenolate mofetil.Approved
MorphineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nabumetone.Approved
NadololMycophenolate mofetil may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMycophenolate mofetil may increase the anticoagulant activities of Nadroparin.Approved
NafamostatMycophenolate mofetil may increase the anticoagulant activities of Nafamostat.Investigational
NafcillinThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Naftifine.Approved
Nalidixic AcidMycophenolate mofetil may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaltrexoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Naproxen.Approved, Vet Approved
NaringeninThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with NCX 4016.Investigational
NeamineMycophenolate mofetil may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneThe metabolism of Mycophenolate mofetil can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Nelfinavir.Approved
NemonoxacinMycophenolate mofetil may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinMycophenolate mofetil may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NeostigmineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nepafenac.Approved
NetilmicinMycophenolate mofetil may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NetupitantThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Mycophenolate mofetil can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Mycophenolate mofetil can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nimesulide.Approved, Withdrawn
NisoldipineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nitroaspirin.Investigational
NorethisteroneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Norethisterone.Approved
NorfloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Ofloxacin.Approved
OlaparibThe metabolism of Mycophenolate mofetil can be decreased when combined with Olaparib.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mycophenolate mofetil.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Olopatadine.Approved
OlsalazineMycophenolate mofetil may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Mycophenolate mofetil.Investigational
OmeprazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Osimertinib.Approved
OtamixabanMycophenolate mofetil may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oxaprozin.Approved
OxprenololMycophenolate mofetil may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oxyphenbutazone.Withdrawn
P-NitrophenolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Palmitic Acid.Experimental
PamidronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pamidronate.Approved
PantoprazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Parecoxib.Approved
ParomomycinMycophenolate mofetil may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Paroxetine.Approved, Investigational
PazufloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololMycophenolate mofetil may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Mycophenolate mofetil can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateMycophenolate mofetil may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Perindopril.Approved
PhenindioneMycophenolate mofetil may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Mycophenolate mofetil can be increased when combined with Phenobarbital.Approved
PhenprocoumonMycophenolate mofetil may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Mycophenolate mofetil can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mycophenolate mofetil.Approved, Investigational
PimozideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Pimozide.Approved
PindololMycophenolate mofetil may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Mycophenolate mofetil can be decreased when combined with Pioglitazone.Approved, Investigational
PirarubicinMycophenolate mofetil may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideMycophenolate mofetil may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mycophenolate mofetil.Approved, Investigational
Platelet Activating FactorThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Platelet Activating Factor.Experimental
PlicamycinMycophenolate mofetil may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mycophenolate mofetil.Approved
PonatinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololMycophenolate mofetil may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Mycophenolate mofetil.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Prasterone.Approved, Nutraceutical
PravastatinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Prazosin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Mycophenolate mofetil can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Propacetamol.Approved
PropafenoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Mycophenolate mofetil.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Mycophenolate mofetil.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Mycophenolate mofetil.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Mycophenolate mofetil.Vet Approved
Protein CMycophenolate mofetil may increase the anticoagulant activities of Protein C.Approved
Protein S humanMycophenolate mofetil may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMycophenolate mofetil may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Protriptyline.Approved
PrulifloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with PTC299.Investigational
PuromycinMycophenolate mofetil may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuercetinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Mycophenolate mofetil.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mycophenolate mofetil.Approved
QuinidineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Quinine.Approved
RabeprazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Rabeprazole.Approved, Investigational
Rabies vaccineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Mycophenolate mofetil.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mycophenolate mofetil.Approved
RanitidineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Regorafenib.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mycophenolate mofetil.Approved
ReserpineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Resveratrol.Experimental, Investigational
ReviparinMycophenolate mofetil may increase the anticoagulant activities of Reviparin.Approved
RibostamycinMycophenolate mofetil may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifabutinThe metabolism of Mycophenolate mofetil can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Mycophenolate mofetil can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Mycophenolate mofetil can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Rilpivirine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Risedronate.Approved, Investigational
RitonavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanMycophenolate mofetil may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Rofecoxib.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Mycophenolate mofetil.Approved
RolapitantThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Rolapitant.Approved
RosiglitazoneThe metabolism of Mycophenolate mofetil can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinMycophenolate mofetil may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Mycophenolate mofetil.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mycophenolate mofetil.Experimental
SaquinavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Mycophenolate mofetil.Investigational
ScopolamineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Mycophenolate mofetil can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Seratrodast.Approved, Investigational
SertralineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Mycophenolate mofetil can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mycophenolate mofetil.Approved
SirolimusThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Sirolimus.Approved, Investigational
SisomicinMycophenolate mofetil may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SorafenibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolMycophenolate mofetil may decrease the antihypertensive activities of Sotalol.Approved
SP1049CMycophenolate mofetil may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinMycophenolate mofetil may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Mycophenolate mofetil.Approved
SpironolactoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with SRT501.Investigational
St. John's WortThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StaurosporineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Stiripentol.Approved
StreptomycinMycophenolate mofetil may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinMycophenolate mofetil may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfamethoxazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineMycophenolate mofetil may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfinpyrazoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Mycophenolate mofetil.Approved
SulodexideMycophenolate mofetil may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Mycophenolate mofetil.Investigational
SumatriptanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Suprofen.Approved, Withdrawn
TacrineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Mycophenolate mofetil.Approved, Investigational
TacrolimusThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Tacrolimus.Approved, Investigational
TacrolimusMycophenolate mofetil may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Mycophenolate mofetil.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Mycophenolate mofetil.Approved
TamoxifenThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Tamoxifen.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mycophenolate mofetil.Approved
Taurocholic AcidThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Taurocholic Acid.Experimental
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Technetium Tc-99m Medronate.Approved
TelaprevirThe metabolism of Mycophenolate mofetil can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Mycophenolate mofetil can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Mycophenolate mofetil.Experimental, Investigational
TemsirolimusThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Temsirolimus.Approved
TenofovirThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mycophenolate mofetil.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tepoxalin.Vet Approved
TerazosinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Mycophenolate mofetil can be decreased when combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tiludronate.Approved, Vet Approved
TimololMycophenolate mofetil may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tixocortol.Approved
TobramycinMycophenolate mofetil may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Tocilizumab.Approved
TofacitinibMycophenolate mofetil may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mycophenolate mofetil.Approved
TolvaptanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Tolvaptan.Approved
TorasemideMycophenolate mofetil may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mycophenolate mofetil.Approved
TranilastThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Mycophenolate mofetil.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mycophenolate mofetil.Approved
TrazodoneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mycophenolate mofetil.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMycophenolate mofetil may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Vet Approved
TrifluoperazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Trimipramine.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Trisalicylate-choline.Approved
TroleandomycinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mycophenolate mofetil.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinMycophenolate mofetil may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mycophenolate mofetil.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Mycophenolate mofetil.Approved
VenlafaxineThe metabolism of Mycophenolate mofetil can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Mycophenolate mofetil can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinMycophenolate mofetil may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMycophenolate mofetil may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Mycophenolate mofetil may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zileuton.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Mycophenolate mofetil can be decreased when combined with Ziprasidone.Approved
Zoledronic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zomepirac.Withdrawn
ZorubicinMycophenolate mofetil may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Do not take calcium, aluminium, magnesium or iron supplements within 2 hours of taking this medication.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
References
Synthesis Reference

Roger C. Fu, De-Mei Leung, Jeffrey S. Fleitman, Michele C. Rizzolio, Andrew R. Miksztal, “Process for preparing pharmaceutical compositions containing crystalline anhydrous mycophenolate mofetil salts.” U.S. Patent US5545637, issued November, 1988.

US5545637
General References
  1. Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS: Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess. 2005 May;9(21):1-179, iii-iv. [PubMed:15899149 ]
  2. Picard N, Cresteil T, Premaud A, Marquet P: Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004 Dec;26(6):600-8. [PubMed:15570183 ]
External Links
ATC CodesNot Available
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (200 KB)
MSDSDownload (82.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8938
Blood Brain Barrier+0.8594
Caco-2 permeable+0.5904
P-glycoprotein substrateSubstrate0.8908
P-glycoprotein inhibitor IInhibitor0.8381
P-glycoprotein inhibitor IIInhibitor0.8061
Renal organic cation transporterInhibitor0.5379
CYP450 2C9 substrateNon-substrate0.8528
CYP450 2D6 substrateNon-substrate0.602
CYP450 3A4 substrateSubstrate0.7646
CYP450 1A2 substrateNon-inhibitor0.6878
CYP450 2C9 inhibitorNon-inhibitor0.9155
CYP450 2D6 inhibitorNon-inhibitor0.7684
CYP450 2C19 inhibitorNon-inhibitor0.9122
CYP450 3A4 inhibitorNon-inhibitor0.8316
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8664
Ames testNon AMES toxic0.6484
CarcinogenicityNon-carcinogens0.953
BiodegradationNot ready biodegradable0.658
Rat acute toxicity3.0412 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.771
hERG inhibition (predictor II)Non-inhibitor0.7653
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Roche palo alto llc
  • Accord healthcare inc usa
  • Apotex corp
  • Endo pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Sandoz inc
  • Strides arcolab ltd
  • Teva pharmaceuticals usa
  • Zydus pharmaceuticals usa inc
  • Accord healthcare inc
  • Apotex inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral250 mg/1
CapsuleOral250 mg
Injection, powder, for solutionIntravenous500 mg
Injection, powder, lyophilized, for solutionIntravenous500 mg/20mL
Powder, for suspensionOral200 mg/mL
Powder, for suspensionOral200 mg
TabletOral500 mg
Tablet, film coatedOral500 mg/1
Powder, for solutionIntravenous500 mg
TabletOral500 mg/1
Tablet, coatedOral500 mg/1
Tablet, film coatedOral500 mg
Prices
Unit descriptionCostUnit
CellCept 200 mg/ml Suspension 175ml Bottle875.84USD bottle
Cellcept 500 mg vial65.03USD vial
Cellcept 500 mg tablet10.43USD tablet
Mycophenolate Mofetil 500 mg tablet8.25USD tablet
Mycophenolate 500 mg tablet7.93USD tablet
CellCept 250 mg capsule5.21USD capsule
Mycophenolate Mofetil 250 mg capsule4.13USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1333285 No1994-11-292011-11-29Canada
CA2172506 No2007-07-172014-09-27Canada
US5543408 No1993-09-152013-09-15Us
US5688529 No1994-11-182014-11-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySlightly soluble (43 mg/mL at pH 7.4)Not Available
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.095 mg/mLALOGPS
logP2.17ALOGPS
logP3.47ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)9.76ChemAxon
pKa (Strongest Basic)6.19ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area94.53 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity117.1 m3·mol-1ChemAxon
Polarizability45.55 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phthalides. These are compounds containing a 3-hydrocarbylidene-2-benzofuran-1(3H)-one moiety,.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsobenzofurans
Sub ClassIsobenzofuranones
Direct ParentPhthalides
Alternative Parents
Substituents
  • Phthalide
  • Methoxyphenol
  • Anisole
  • Fatty acid ester
  • Alkyl aryl ether
  • Fatty acyl
  • Benzenoid
  • Oxazinane
  • Morpholine
  • Dicarboxylic acid or derivatives
  • Vinylogous acid
  • Tertiary aliphatic amine
  • Tertiary amine
  • Lactone
  • Carboxylic acid ester
  • Oxacycle
  • Azacycle
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Rna binding
Specific Function:
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in t...
Gene Name:
IMPDH1
Uniprot ID:
P20839
Molecular Weight:
55405.365 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Bremer S, Rootwelt H, Bergan S: Real-time PCR determination of IMPDH1 and IMPDH2 expression in blood cells. Clin Chem. 2007 Jun;53(6):1023-9. Epub 2007 Apr 26. [PubMed:17463174 ]
  4. Wang J, Yang JW, Zeevi A, Webber SA, Girnita DM, Selby R, Fu J, Shah T, Pravica V, Hutchinson IV, Burckart GJ: IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther. 2008 May;83(5):711-7. Epub 2007 Sep 12. [PubMed:17851563 ]
  5. Sanquer S, Maison P, Tomkiewicz C, Macquin-Mavier I, Legendre C, Barouki R, Lang P: Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation. Clin Pharmacol Ther. 2008 Feb;83(2):328-35. Epub 2007 Aug 22. [PubMed:17713475 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Rna binding
Specific Function:
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in t...
Gene Name:
IMPDH2
Uniprot ID:
P12268
Molecular Weight:
55804.495 Da
References
  1. Vannozzi F, Filipponi F, Di Paolo A, Danesi R, Urbani L, Bocci G, Catalano G, De Simone P, Mosca F, Del Tacca M: An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc. 2004 Nov;36(9):2787-90. [PubMed:15621150 ]
  2. Bremer S, Rootwelt H, Bergan S: Real-time PCR determination of IMPDH1 and IMPDH2 expression in blood cells. Clin Chem. 2007 Jun;53(6):1023-9. Epub 2007 Apr 26. [PubMed:17463174 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A7
Uniprot ID:
Q9HAW7
Molecular Weight:
59818.315 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 3 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).
Gene Name:
UGT1A6
Uniprot ID:
P19224
Molecular Weight:
60750.215 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6. [PubMed:15470161 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6. [PubMed:15470161 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A8
Uniprot ID:
Q9HAW9
Molecular Weight:
59741.035 Da
References
  1. Thervet E, Anglicheau D, Legendre C: [Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7. [PubMed:11817210 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein kinase c binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A10
Uniprot ID:
Q9HAW8
Molecular Weight:
59809.075 Da
References
  1. Thervet E, Anglicheau D, Legendre C: [Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7. [PubMed:11817210 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Triglyceride lipase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity,...
Gene Name:
CES1
Uniprot ID:
P23141
Molecular Weight:
62520.62 Da
References
  1. Fujiyama N, Miura M, Kato S, Sone T, Isobe M, Satoh S: Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil. Drug Metab Dispos. 2010 Dec;38(12):2210-7. doi: 10.1124/dmd.110.034249. Epub 2010 Sep 7. [PubMed:20823294 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Methylumbelliferyl-acetate deacetylase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Shows high catalytic efficiency for hydrolysis of cocaine, 4-methylumbelliferyl acetate, heroin and 6-monoacetylmorphine.
Gene Name:
CES2
Uniprot ID:
O00748
Molecular Weight:
61806.41 Da
References
  1. Fujiyama N, Miura M, Kato S, Sone T, Isobe M, Satoh S: Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil. Drug Metab Dispos. 2010 Dec;38(12):2210-7. doi: 10.1124/dmd.110.034249. Epub 2010 Sep 7. [PubMed:20823294 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Picard N, Cresteil T, Premaud A, Marquet P: Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004 Dec;26(6):600-8. [PubMed:15570183 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Picard N, Cresteil T, Premaud A, Marquet P: Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004 Dec;26(6):600-8. [PubMed:15570183 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Picard N, Cresteil T, Premaud A, Marquet P: Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004 Dec;26(6):600-8. [PubMed:15570183 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T: Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9. Epub 2007 Sep 29. [PubMed:17906856 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Michelon H, Konig J, Durrbach A, Quteineh L, Verstuyft C, Furlan V, Ferlicot S, Letierce A, Charpentier B, Fromm MF, Becquemont L: SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics. 2010 Dec;11(12):1703-13. doi: 10.2217/pgs.10.132. [PubMed:21142914 ]
  2. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T: Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9. Epub 2007 Sep 29. [PubMed:17906856 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T: Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9. Epub 2007 Sep 29. [PubMed:17906856 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Miura M, Kagaya H, Satoh S, Inoue K, Saito M, Habuchi T, Suzuki T: Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64. doi: 10.1097/FTD.0b013e3181838063. [PubMed:18695635 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Miura M, Kagaya H, Satoh S, Inoue K, Saito M, Habuchi T, Suzuki T: Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64. doi: 10.1097/FTD.0b013e3181838063. [PubMed:18695635 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:47